Predicting Patient Response Before Trials Start: Pilgrim Jackson, Yatiri Bio

What if you could know before a clinical trial which patients will respond? Not after Phase 2 fails. Not after spending $50M. Before you even start.In this episode, Pilgrim Jackson, CEO of Yatiri Bio, shares how his company is using proteomics to predict treatment response in AML and ovarian cancer with 100% accuracy so far.What we discuss:• How proteomic signatures differentiate responders from non-responders in AML and ovarian cancer• Why this could reduce Phase 2 trial enrollment from 100 patients to 40—cutting costs in half• De-risking clinical trial design and addressing patient heterogeneity• Regulatory considerations for biomarker-driven and stratified trials• The future of precision oncology and patient-centric trial designThis isn't incremental improvement. This is a completely different way to run trials.About the Guest: Pilgrim Jackson is CEO of Yatiri Bio, a biotechnology company decoding proteins to predict treatment response in oncology.About the Show: Innovating Tomorrow's Medicine features conversations with biotech leaders, researchers, and innovators who are transforming bold ideas into real-world impact in healthcare and life sciences.🔗 Connect:• Yatiri Bio: [https://yatiribio.com]• Pilgrim Jackson:[https://www.linkedin.com/in/pilgrimjackson]• Host Jeff Trickett: [https://www.linkedin.com/in/jeff-trickett]📧 Questions or guest suggestions? [[email protected]]#Biotech #ClinicalTrials #PrecisionMedicine #Proteomics #Oncology #AML #DrugDevelopment